Group 1 - The core viewpoint of the news is that Genting New Year (01952) has seen a stock increase of over 3% following the FDA approval of its cardiovascular product, LEROCHOLTM (lerodalcibep-liga), for lowering LDL-C levels in adults with high cholesterol [1] - Genting New Year reported a stock price of 48.44 HKD with a trading volume of 131 million HKD at the time of the announcement [1] - The FDA approval allows for the use of LEROCHOLTM in conjunction with diet and exercise for patients with heterozygous familial hypercholesterolemia (HeFH) [1] Group 2 - LEROCHOLTM is a novel small-molecule protein-binding third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control [2] - As the first PCSK9 inhibitor fusion protein, LEROCHOLTM has low immunogenicity and outstanding safety [2] - The product is developed for patient convenience, allowing for self-administration with a single subcutaneous injection once a month, and has a long room temperature stability of up to 3 months [2]

Core Viewpoint - CloudTop New Horizon (01952) shares rose over 3% following FDA approval of its cardiovascular product LEROCHOLTM (lerodalcibep-liga) for lowering LDL-C levels in adults with high cholesterol [1][2] Group 1: Company Developments - The FDA approved the biologics license application (BLA) for LEROCHOLTM, which is intended for use alongside diet and exercise to reduce LDL-C levels in patients with high cholesterol, including heterozygous familial hypercholesterolemia (HeFH) [1] - In December 2025, CloudTop New Horizon signed a licensing agreement with Haisan Bio to obtain exclusive rights for the further clinical development, registration, and commercialization of LEROCHOLTM in Greater China [1] Group 2: Product Features - LEROCHOLTM is a novel small-molecule protein-binding third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets [2] - As the first PCSK9 inhibitor fusion protein, LEROCHOLTM has low immunogenicity and outstanding safety [2] - The product is designed for patient convenience, allowing self-administration with a single small-volume subcutaneous injection once a month, and has a long room-temperature stability of up to 3 months, making it easy for patients to store and carry [2]

Group 1: Core Insights - The FDA has approved the biologics license application (BLA) for LEROCHOL TM (lerodalcibep-liga), a cardiovascular product from LIB Therapeutics, which aims to lower LDL-C levels in adults with high cholesterol [1] - Cloudtop New Horizon has secured exclusive rights for the clinical development, registration, and commercialization of LEROCHOL in Greater China through a licensing agreement with Haisan Biotech, with plans to submit a BLA in 2026 [1] - The product is expected to drive growth in the company's cardiovascular business, with potential market entry as early as 2027 [1] Group 2: Product Advantages - LEROCHOL is a third-generation PCSK9 inhibitor with three core advantages: low immunogenicity, convenient self-administration with a monthly injection, and flexible storage for up to three months at room temperature [2] - Clinical trials involving over 2,900 patients have shown that LEROCHOL can reduce LDL-C levels by ≥60% in cardiovascular disease patients and by 59% in HeFH patients [2] - A key registration phase III clinical trial in China has demonstrated significant efficacy and safety, achieving primary and secondary endpoints related to LDL-C reduction and atherosclerotic lipid improvement [2] Group 3: Market Demand and Potential - Cardiovascular diseases are a leading cause of death globally and in China, with elevated LDL-C levels being a critical factor in severe cardiovascular events [3] - There is a significant unmet medical need in China, where approximately 400 million people have dyslipidemia, and only 14% receive lipid-lowering treatment [3] - The PCSK9 inhibitor market in China is projected to reach approximately 3 billion yuan in 2024, with a 95% year-on-year growth, and is expected to expand to around 10 billion yuan by 2030 [3] Group 4: Commercial Strategy - Cloudtop New Horizon has established an integrated system driven by scientific and commercial insights for medical, access, market, and sales collaboration, which has been validated in other therapeutic areas [3] - The company aims to leverage this system to ensure successful commercialization of LEROCHOL in the cardiovascular sector in Greater China [3]

Core Viewpoint - The approval of LEROCHOLTM (lerodalcibep-liga) by the FDA marks a significant advancement for the cardiovascular treatment landscape, particularly for patients with high cholesterol levels, including heterozygous familial hypercholesterolemia (HeFH) [1][2][4]. Group 1: Product Overview - LEROCHOLTM is a third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets, with a low immunogenicity profile and excellent safety [2][3]. - The product allows for self-administration with a single subcutaneous injection once a month, offering convenience and stability for patients [2]. - In global Phase III clinical trials involving over 2,900 patients, LEROCHOLTM demonstrated a sustained LDL-C reduction of ≥60% in cardiovascular disease patients and a 59% reduction in HeFH patients [2][3]. Group 2: Clinical Trial Results - The Phase III clinical trial in China for LEROCHOLTM has shown promising results, achieving primary efficacy endpoints for LDL-C reduction and demonstrating good safety and tolerability compared to placebo [3]. - The ongoing high prevalence of elevated LDL-C levels among cardiovascular disease patients highlights the unmet medical needs in this area, with only about 14% of the 400 million individuals with dyslipidemia in China receiving treatment [3]. Group 3: Market Potential - The PCSK9 inhibitor market in China is projected to grow significantly, with an estimated market size of approximately RMB 3 billion in 2024, reflecting a 95% year-on-year increase [6]. - By 2030, the market is expected to expand to around RMB 10 billion, indicating substantial growth potential for LEROCHOLTM, which benefits from a patent exclusivity period until 2039 [6]. Group 4: Commercialization Strategy - The FDA approval of LEROCHOLTM represents a strategic milestone for the company in the cardiovascular and metabolic field, with plans to submit a BLA in China in the first half of next year [1][5]. - The company has established a comprehensive commercialization system that integrates medical insights, market access, and sales, which has been successfully validated in other therapeutic areas [5].

Core Viewpoint - The FDA has approved the biologics license application (BLA) for LEROCHOL (lerodalcibep-liga), a novel cardiovascular product developed by LIB Therapeutics, which is expected to significantly enhance the long-term growth of the cardiovascular business for Cloudtop New Horizon (1952.HK) in Greater China [1][5]. Group 1: Product Overview - LEROCHOL is a third-generation PCSK9 inhibitor designed to help patients achieve and maintain LDL-C control targets, with a low immunogenic profile and excellent safety [2]. - The product allows for self-administration with a single subcutaneous injection once a month, offering convenience for patients [2]. - In global Phase III clinical trials involving over 2,900 patients, LEROCHOL demonstrated a sustained LDL-C reduction of ≥60% in cardiovascular disease patients and a 59% reduction in HeFH patients [2]. Group 2: Clinical Trial Results - The Phase III clinical trial in China has shown promising results, achieving primary efficacy endpoints for LDL-C reduction and demonstrating good safety and tolerability compared to placebo [3]. - High LDL-C levels are a key risk factor for serious cardiovascular events, and lowering LDL-C can improve patient outcomes [3]. Group 3: Market Potential - The PCSK9 inhibitor market in China is projected to grow rapidly, with a market size of approximately RMB 3 billion in 2024, reflecting a 95% year-on-year increase [6]. - By 2030, the market size is expected to expand to around RMB 10 billion, indicating significant growth potential [6]. - LEROCHOL's unique product advantages and solid clinical data, along with patent protection until 2039, position it well to capture a significant market share in a competitive landscape [6]. Group 4: Commercialization Strategy - Cloudtop New Horizon has established a comprehensive commercialization system, which has been successfully validated in other therapeutic areas, to facilitate the market penetration of LEROCHOL [5]. - The company plans to submit the BLA for LEROCHOL in Greater China in the first half of next year, with potential market entry as early as 2027 [5].

Core Viewpoint - Amgen's drug Repatha® (evolocumab injection) has shown significant efficacy in reducing the incidence of first major cardiovascular events by 25% and first myocardial infarctions by 36% in high-risk patients without prior events, supporting the broader application of PCSK9 inhibitors [1] Group 1 - Amgen's stock price increased by 0.9% following the announcement of the VESALIUS-CV study results [1] - The VESALIUS-CV study results indicate a substantial reduction in cardiovascular events, which may enhance the market potential for PCSK9 inhibitors [1]

Core Points - The 2025 National Medical Insurance Directory negotiations have officially commenced, highlighting the importance of pharmaceutical innovation and patient access to medications [1] - The atmosphere at the negotiations is characterized by a cautious and low-key approach from pharmaceutical representatives, with an increased emphasis on confidentiality [3][4] - A total of 535 drugs are under review, with 311 outside the directory and 224 within it, alongside 121 high-value drugs reviewed under the commercial insurance innovation drug directory [9][10] Group 1: Negotiation Atmosphere - The entry process for pharmaceutical representatives was notably quieter and more orderly compared to previous years, reflecting a more subdued approach [3][4] - Representatives from both domestic and multinational pharmaceutical companies, including notable names like 恒瑞医药 and 阿斯利康, participated in the negotiations [4][9] Group 2: Key Drug Categories - Antibacterial drugs are expected to be a significant focus in the afternoon session of the negotiations, with specific products like 万古霉素 being highlighted [9][10] - Innovative drugs, including CAR-T products and new lipid-lowering medications, are also under consideration, with 恒瑞医药 presenting multiple products for initial review [10][12] Group 3: Market Insights - The PCSK9 inhibitor 瑞卡西单抗 has gained attention for its long-acting properties, with a market size of 1.32 billion yuan in 2023, representing 7.8% of the national lipid-lowering drug market [10][11] - The long-acting 阿立哌唑微球 from 丽珠集团 is another product of interest, potentially replacing oral formulations and capturing market share if included in the insurance directory [12]

Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized for its potential as a strong investment, particularly highlighted in the context of Roth IRA stocks [1][4]. Group 1: Clinical Trial Results - Merck reported positive topline results from its Phase 3 CORALreef Lipids trial for enlicitide decanoate, an investigational oral PCSK9 inhibitor for hypercholesterolemia, on September 2, 2025 [2]. - The study met all endpoints, showing significant reductions in LDL-C, non-HDL-C, ApoB, and Lp(a) compared to placebo at Week 24 [3]. - Safety outcomes were favorable, with low discontinuation rates and no significant differences in adverse events between treatment groups, reinforcing the drug's promise as the first oral macrocyclic peptide PCSK9 inhibitor [3]. Group 2: Company Overview - Merck & Co., Inc. is a global biopharmaceutical company focused on developing innovative medicines, vaccines, and health solutions aimed at saving and improving lives worldwide [4].

Financial Data and Key Metrics Changes - Merck is in a transformation phase with a diversified set of growth drivers, aiming for over $50 billion in revenues by the mid-2030s from its pipeline [3][4] - The company is launching 20 products, most of which have blockbuster potential [3][4] Business Line Data and Key Metrics Changes - KEYTRUDA continues to show strong growth with 42 approved indications in the U.S. across 18 tumor types, with expectations for continued growth from new indications [6][7] - The subcutaneous formulation of KEYTRUDA is anticipated to achieve 30% to 40% adoption within 18 to 24 months post-launch [9][11] Market Data and Key Metrics Changes - The company is well-positioned to manage the impact of tariffs and has a diverse supply chain footprint [41][42] - The impact of the Most Favored Nation (MFN) policy is expected to be manageable, as it only accounts for less than 10% of revenues [42][43] Company Strategy and Development Direction - Merck is focused on innovation and expanding its pipeline, with plans to increase R&D investments due to a strong pipeline of 80 Phase III clinical programs [51][52] - Business development remains a priority, with a focus on bringing in innovative science that addresses unmet medical needs [67][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the loss of exclusivity for KEYTRUDA and emphasized the importance of their pipeline in driving future growth [5][6] - The company is optimistic about the readouts from its oncology and HIV pipelines in the coming year [80][81] Other Important Information - The company is preparing for the launch of its oral PCSK9 inhibitor, which is expected to democratize access to this treatment [60][62] - Merck is also excited about its cancer vaccine program, focusing on early-stage cancers with potential curative opportunities [39][40] Q&A Session Summary Question: What are the growth avenues for KEYTRUDA? - Management expects continued growth from new indications, including early-stage lung cancer and women's cancers [7][8] Question: How will the adoption of the subcutaneous formulation of KEYTRUDA be affected? - Factors such as pricing, access, and the J code will influence adoption rates, with expectations of 30% to 40% adoption within 18 to 24 months [10][11] Question: What is the confidence level in the TROP-two ADC program? - Management expressed confidence based on early signals and extensive clinical trials, highlighting its unique properties and potential in maintenance settings [17][18] Question: How does Merck plan to address macroeconomic headwinds like tariffs? - The company has a diverse supply chain and is well-positioned to manage tariff impacts, focusing on innovation and product launches [41][42] Question: What is the outlook for Gardasil in China? - Gardasil is not expected to drive significant growth in China, with future growth anticipated from international markets and new product launches [69][70] Question: What are the expectations for the cancer vaccine program? - The program is focused on early-stage cancers, with positive readouts expected in the next couple of years [39][40]

Core Viewpoint - Merck (MRK.US) announced positive results from the Phase III CORALreef Lipids study for Enlicitide, a treatment for hypercholesterolemia, marking the largest Phase III study completed for this drug [1] Group 1: Study Results - The CORALreef Lipids study is the largest Phase III trial completed for Enlicitide, which has previously successfully completed two other Phase III studies [1] - Enlicitide (MK-0616) is an oral cyclic peptide PCSK9 inhibitor developed by Merck [1] Group 2: Mechanism of Action - PCSK9 (proprotein convertase subtilisin/kexin type 9) is primarily expressed in the liver and is a contributor to elevated levels of "bad cholesterol" LDL-C [1] - PCSK9 binds to receptors on liver cells responsible for clearing LDL-C, resulting in a significant portion of LDL-C being unable to be absorbed [1]